AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

Let us discuss how some of its key drugs performed in the quarter So far this year, Amgen’s stock has risen 8.8% against the industry‘s 1.4% decline. In general medicine, Repatha is Amgen’s ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...

Q1 2025. Management View. CEO Robert Bradway emphasized a strong start to 2025, highlighting 9% year-over-year revenue growth and 14% vol ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...

with management highlighting differentiated profiles for MariTide and Repatha as mitigating factors. Amgen’s Q1 2025 earnings call highlighted strong revenue and volume growth, driven by key ...

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ...

Amgen (NasdaqGS:AMGN) recently reported strong financial results for Q1 2025, showing a turnaround from a loss to a ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...